Relationship between<em>UGT1A1</em>gene polymorphisms and toxicity of irinotecan-based chemotherapy in colorectal cancer

周琰; 庄荣源; 陈朴; 谈绮文; 张春燕; 郭玮; 刘天舒; 潘柏申

doi:10.3969/j.issn.1007-3969.2014.07.003

您当前的位置：

首页 >

文章列表页 >

Relationship betweenUGT1A1gene polymorphisms and toxicity of irinotecan-based chemotherapy in colorectal cancer

更新时间：2025-12-31

- Relationship betweenUGT1A1gene polymorphisms and toxicity of irinotecan-based chemotherapy in colorectal cancer
- China Oncology Vol. 24, Issue 7, Pages: 493-500(2014)
- 作者机构：
  
  1. 复旦大学附属中山医院检验科,上海,200032
  2. 复旦大学附属中山医院肿瘤内科,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.07.003
  CLC：
- Published Online：29 July 2014，
  
  Published：29 July 2014
- 稿件说明：
移动端阅览
周琰,庄荣源,陈朴,谈绮文,张春燕,郭玮,刘天舒,潘柏申.

周琰, 庄荣源, 陈朴, et al. Relationship betweenUGT1A1gene polymorphisms and toxicity of irinotecan-based chemotherapy in colorectal cancer[J]. China Oncology, 2014, 24(7): 493-500.
周琰,庄荣源,陈朴,谈绮文,张春燕,郭玮,刘天舒,潘柏申. DOI： 10.3969/j.issn.1007-3969.2014.07.003.

周琰, 庄荣源, 陈朴, et al. Relationship betweenUGT1A1gene polymorphisms and toxicity of irinotecan-based chemotherapy in colorectal cancer[J]. China Oncology, 2014, 24(7): 493-500. DOI： 10.3969/j.issn.1007-3969.2014.07.003.

摘要

背景与目的：尿苷二磷酸葡萄糖醛酸转移酶1A1(uridine diphosphoglucu-ronosyltransferase 1A1，UGTlA1)是伊立替康代谢关键酶，其活性受基因多态性影响显著。本研究探讨结直肠癌患者中，UGT1A1*28和UGT1A1*6基因多态性与伊立替康治疗相关不良反应之间的关系。方法：入组2013年4月—2013年12月于复旦大学附属中山医院肿瘤内科接受治疗的消化道恶性肿瘤患者160例。抽提外周血中基因组DNA，分别采用STR方法和Sanger测序法，检测UGT1A1*28和UGT1A1*6基因型，分析UGT1A1基因多态性分布情况。对其中82例化疗方案中含伊立替康的结直肠癌患者进行随访，记录不良反应发生情况和严重程度，比较不同基因型患者之间的差异。结果：160例消化道肿瘤患者中，UTG1A1*28(启动子TATA盒区域TA重复次数)野生型TA6/6124例(77.5%)；杂合子TA6/7 33例(20.5%)；纯合子TA7/7 3例(2.0%)。UGT1A1*6位点(211GA)野生型GG 105例(65.6%)，杂合子GA 48例(30.0%)；纯合子AA 7例(4.4%)。82例化疗方案中含伊立替康的结直肠癌患者中，*28基因型(TA6/7和TA7/7)显著增加发生3级以上中性粒细胞减少的风险(58.3% vs 0.0%，P0.001)，并增加整体不良反应发生率(76.0% vs 45.6%，P0.001)；*6基因型(GA和AA)、年龄、性别、化疗方案和伊立替康相关不良反应发生无显著相关性。结论：接受伊立替康化疗的结直肠癌患者，UGT1A1*28位点多态性显著增加中性粒细胞减少发生的风险，可预测伊立替康引起的骨髓抑制性不良反应，辅助临床选择合适的化疗方案。

Abstract

Background and purpose: Uridine diphosphoglucu-ronosyl transferase 1A1 (UGT1A1) is an important enzyme for metabolism of irinotecan. The activity of UGT1A1 enzyme was significantly affected by the gene polymorphism. This study aimed to investigate the correlation of UGT1A1*28 and *6 gene polymorphisms with irinotecan-based chemotherapy in colorectal cancer(CRC). Methods: Analysis of UGT1A1*28 and *6 gene polymorphisms was performed in 160 gastrointestinal cancer patients admitted to Zhongshan Hospital Fudan University from Apr. 2013 to Dec. 2013 by amplifying the gene fragments using PCR

STR and Sanger sequencing. Eighty-two cases with CRC treated with irinotecan were chosen to observe the adverse events during chemotherapy. The incidence of different genotypes was compared. Results: The distribution of the genotypes in 160 gastrointestinal cancer patients was as followed: UGT1A1*28 wild-type genotype TA6/6 (124

77.5%)

heterozygous genotype TA6/7 (33

20.5%)

and homozygous genotype TA7/7 (3

2.0%); UGT1A1*6 wild-type genotype GG (105

65.6%)

heterozygous genotype GA (48

30.0%)

and homozygous genotype AA (7

4.4%). In the 82 CRC cases

the incidences of grade 3 and 4 neutropenia in the patients carrying UGT1A1*28 (TA6/7+ TA7/7 ) were higher than those in the WT genotype (TA6/6) (58.3% vs 0.0

P0.001)

and increased the total incidence of adverse events (76.0% vs 45.6%

P0.001). There was no significant relevance between UGT1A1*6 genotype

age

gender chemotherapy and adverse events. Conclusion: In the CRC cases with irinotecan-based chemotherapy

the UGT1A1*28 (TA6/7+TA7/7) genotype significantly increased the risk of grade 3 and 4 neutropenia. Detecting UGT1A1 gene polymorphisms may guide individualized treatment and predict adverse events.

关键词

Keywords

references

Views

5272

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeted therapy and immunotherapy combined with chemotherapy bring effective response to AFP positive colon cancer patients: a case report and literature review

Mechanisms underlying tepoxalin-mediated regulation of cell growth and chemoresistance via ABCB1 in colorectal cancer

Research progress and prospects of exercise intervention in comprehensive management of colorectal cancer

Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer

The impact of participation status on the colorectal cancer incidence, stage and survival outcomes in the Shanghai colorectal cancer screening program

Related Author

LIU Miao

LI Jinze

WU Chensi

ZHANG Fengbin

GAO Hongsheng

ZHANG Ruixing

Zhijun HE

Liwen JIN

Related Institution

Department of Gastroenterology, the Fourth Hospital of Hebei Medical University

Department of Pathology, the Fourth Hospital of Hebei Medical University

Department of General Surgery, Shanghai Pudong New District Zhoupu Hospital

Department of Gastroenterology, Shanghai Pudong New District Zhoupu Hospital

Cancer Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰

Relationship betweenUGT1A1gene polymorphisms and toxicity of irinotecan-based chemotherapy in colorectal cancer

DOI：10.3969/j.issn.1007-3969.2014.07.003

摘要

Abstract

关键词

Keywords

references